Alcohol interaction trial enhanced with responsive, collaborative approach, says CRO

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/OlegEvseev)
(Image: Getty/OlegEvseev)

Related tags Clinical trial Contract research organization Clinical research

Vince & Associates Clinical Research is conducting a Phase Ib alcohol interaction study of Amygdala Neurosciences’ ANS-6637 for the potential treatment of substance abuse.

An Altasciences company, Vince & Associates Clinical Research is a contract research organization (CRO) based in Overland Park, KS.

The proof-of-concept, dose-ranging study will evaluate the safety of the co-administration of ascending doses of ANS-6637 and ethanol in healthy male alcohol drinkers, according to the company.

Amygdala Neurosciences Inc. acquired ANS-6637 (previously GS-6637) from Gilead Sciences, Inc. earlier this year. Its potential clinical indication is the treatment of substance abuse, including alcohol and cocaine dependence.

As for the challenges of conducting the trial, Bradley Vince, D.O., CEO and medical director at Vince & Associates Clinical Research told us the study requires “significant investigator and clinical operations staffing secondary to the necessary safety monitoring and medical hypervigilance​.”

Additionally, recruitment will also be a challenge – as it is across the industry – though specifically, the alcohol interaction trial will require recruitment of qualified volunteers that meet protocol specified eligibility with respect to alcohol consumption history, Vince explained.

It is imperative to utilize a CRO with significant expertise in special populations as well as depth in the Investigator staff secondary to the extensive medical procedures required in alcohol interaction trials​,” he added.

Further, a responsive and collaborative approach by the sponsor with respect to dose escalations further enhances the successful study conduct of these complex clinical trials​,” said Vince.

The CRO has completed five of six dosing cohorts.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more